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Thymic oxytocin (OT) behaves as a cryptocrine signal targeted at the outer
surface of thymic epithelial cell plasma membrane from where OT is able to
interact with neurohypophysial peptide receptors expressed by pre-T cells.
Immature T cells bear a receptor of the V1 subtype, while OT receptors are
predominantly expressed by cytotoxic CD8+ lymphocytes. In both T cell
types, neurohypophysial peptide receptors transduce OT via the phosphoino-
sitide pathway. Protein tyrosine phosphorylation is an early event of T cell
activation. Western blots of murine pre-T cells (RL12-NP line) proteins probed
with anti-phosphotyrosine (PY-20) revealed a great number of proteins the
phosphorylation of which increased either with OT or vasopressin treatment.
Two were immunoprecipitated with anti-focal adhesion kinase (FAK) mAb
2A7 and were identified one as p125FAK and the other as a coprecipitating
130-kDa protein. The p125FAK is connected to the Ras/MAPK pathway and is
also implicated in TCR/CD3 signalling in T cell. Another protein phosphory-
lated by OT in RL12-NP was identified as paxillin, a 68-kDa protein localised
at focal adhesion sites and associated with p125FAK. These results indicate that
phosphorylation of focal adhesion kinase may be induced in pre-T cell by
thymic OT.
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Introduction
The p125FAK is a member of a new family of non-
receptor protein tyrosine kinases (PTK) which is impli-
cated in focal adhesion, as well as in morphogenic and
proliferative processes [1]. Unlike other non-receptor
PTK, it lacks a structure to bind either to membranes or
other cellular proteins, the src homology-2 (SH-2) or SH-3
domains as well as a consensus acylation site [2]. The
COOH-terminal region has been identified to be critical
for efficient localisation to focal adhesion sites [3]. Molec-
ular analysis has shown that the COOH-terminal region
contains a sequence called focal adhesion targeting which
is able to bind to p130Cas and paxillin, and therefore acts
through adaptator proteins Grb2/SoS to activate Ras/
MAPK pathway. This PTK is stimulated in several condi-
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tions including oncogenic transformation and stimulation
with integrins and mitogenic peptides such as bombesin,
endothelin or vasopressin (VP) [4]. The p125FAK is ubi-
quitous and has been immunodetected in human T and
B cells [5].
The thymus is the primary organ of T cell development
and close interactions between differentiating T lympho-
cytes and thymic epithelial cells (TEC) play an important
role in the establishment of positive/negative selection of
T cells [6]. The thymus is a privileged site where the neu-
roendocrine system may modulate T cell differentiation,
and where the immune system is educated to recognize
different neuroendocrine polypeptide families [7, 8]. TEC
are able to present neuroendocrine self-antigens via the
major histocompatibility complex machinery [9, 10]. This
process is thought to induce the central deletion of self-
reactive T cells oriented against neuroendocrine families
[8]. On the other hand, TEC send signals to specific recep-
tors on pre-T cells through a pathway described as crypto-
crine signalling [11].
TEC from different species synthesise neurohypophy-
sial peptides with a marked predominance for oxytocin
(OT) [12, 13]. Immature and cytotoxic T cell lines bear
specific receptors for the neurohypophysial peptide fami-
ly and these receptors are able to transduce neurohypo-
physial signals through the phosphoinositide pathway
[14]. The KD of the receptors is in good accordance with
the concentration of immunoreactive (IR) OT measured
in the human thymus. In addition, the incorporation of
tritiated thymidine is enhanced in freshly isolated human
thymocytes treated with neurohypophysial-related pep-
tides in serum-free medium [14].
An ultrastructural study has shown the diffuse pres-
ence of IR OT in the cytosol of TEC in close contact with
pre-T cells and various points of focal adhesion were evi-
denced between the plasma membranes of TEC and pre-T
cells [15]. Since p125FAK was shown to be implicated in
T cell adhesion [16], we have investigated the hypothesis
that neurohypophysial peptides may be implicated in the




RL12-NP cells are an immature T cell line derived from a murine
radio-induced thymic lymphoma [17]. Neither CD4 nor CD8 have
been found on these cells. They were maintained and propagated for
experimental purposes as previously described [14]. Culture medium
was RPMI 1640 supplemented with 10% FCS (Gibco BRL, Belgium,
Batch 40Q1052J), 2 mM L-glutamine, 100 U/ml penicillin, 100 Ìg/
ml streptomycin, cocktail of non-essential amino acids (Bio-Whitta-
ker, Belgium) and 10 ÌM 2-ß-mercaptoethanol (Gibco BRL, Bel-
gium).
Immunoprecipitations
Cells were washed 3 times with a large volume of Dulbecco’s
modification of phosphate-balanced salt solution without Ca2+ and
Mg2+ (DPBS w/o Ca/Mg) (Bio-Whittaker, Belgium) at 4 °C, 400 g
and resuspended in experimental culture medium (culture medium
without FCS and 2-ß-mercaptoethanol) at 108 cells/ml. This suspen-
sion was diluted to 107 cells/ml in 1 ml experimental medium at
37°C containing appropriate concentrations of the following pep-
tides: VP (Sigma), OT (Sigma) and an antagonist to V1 receptor
d(CH2)5[Tyr(Me)2]AVP(A) (ICN Flow) [18]. The latter has been
successfully used to inhibit RL12-NP cells proliferation [14]. The
moment of dilution was considered to be time 0. Stimulation was
achieved by addition of a 5-fold volume of DPBS w/o Ca/Mg at 4°C.
Protein extraction was done essentially as described elsewhere [19].
Briefly, suspensions were centrifuged at 4 °C, 400 g and lysed at 4°C
by 1 ml of a solution 150 mM NaCl, 0.1% NaN3, 50 mM Tris HCl,
pH 7.6 containing 2 mM EDTA, 1 mM Na o-vanadate, 10 Ìg/ml leu-
peptin, 0.1% triton X-100 and 0.1% Na deoxycholate. The lysates
were preclarified by centrifugation at 12,000 g for 15 min. Superna-
tants were concentrated to 50 Ìl by Centricon SR-10 microconcen-
trator (Amicon Grace, France). Resulting protein concentrations
were measured using the Bradford method in order to normalise the
following operations. Total fractions were either directly submitted
to electrophoresis or immunoprecipitated with anti-p125FAK mono-
clonal antibodies (mAb) 2A7 or anti-paxillin mAb (ICN Flow, clone
349) pre-coupled to protein-A-like agarose and immunoprecipitates
were washed twice with PBS before electrophoresis.
Identification of Phosphotyrosine-Containing Proteins by
Immunoblotting
Cell lysates or immunoprecipitates were boiled for 3 min in SDS
2% sample buffer and submitted to SDS-PAGE on 7.5% gels using
the Schägger and von Jagow [20] procedures. Proteins were trans-
ferred to Immobilon (Millipore, Belgium) and the blot was incubated
12 h at 4°C in NaCl 150 mmol/l, Tris-HCl 50 mmol/l, pH 7.5 (TBS)
containing 1% (w/v) blocking reagent (Boehringer Mannheim block-
ing reagent, Boehringer Mannheim). The blot was probed with anti-
phosphotyrosine mAb PY-20 (ICN Flow, Belgium) at 1/2,000 dilu-
tion for 12 h at 4°C. Immobilon membrane was washed twice in TBS
containing 0.1% Tween and twice in TBS containing 0.5%
(w/v) blocking reagent for 10 min each. Incubation was then per-
formed with 1/2,000 dilution of horseradish peroxidase (HRP)-con-
jugated sheep anti-mouse IgG (Boehringer Mannheim) in TBS with
0.5% (w/v) blocking reagent. Immunoreactivity was determined
using the BM chemiluminescence assay reaction (Boehringer Mann-
heim) called thereafter fluorography. In some cases, anti-phosphoty-
rosine mAb was stripped of membranes after analysis by 1/hour
treatment at 60°C with TBS solution containing 2% Tween-20 and
0.1 M ß-mercaptoethanol. The efficiency of the stripping was con-
firmed by incubating blots in developing reagents and re-exposing to
autoradiography film. Finally, the stripped membrane was probed
with 2A7 anti-FAK in order to confirm similar loading. Quantifica-
tion of phosphorylation was performed using densitometric analysis
of fluorography performed with a Bio-Rad GS-700 imaging densi-
tometer and calculated with the Molecular Analyst 1.4 Bio-Rad soft-
ware. Normalisation of the intensity was made using either the resid-
284 Neuroendocrinology 1998;67:282–289 Martens/Kecha/Charlet-Renard/Defresne/
Geenen
Fig. 1. Induction of phosphorylation in
VP- and OT-treated cells. 107 RL12-NP cells
were incubated for 5 min in absence (C) or in
presence of VP (1 nM) or OT (1 nM) before
addition of cold DPBS w/o Ca/Mg. Lysates
were submitted to electrophoresis and trans-
ferred on Immobilon membranes. Mem-
branes were probed with PY-20 mAb spe-
cific for phosphotyrosine residues. IR pro-
teins were visualised by fluorography. The
basal level of phosphorylation might indi-
cate a constitutive activation of intracellular
proteins related to the lymphomatous nature
of the cell line.
Fig. 2. Comparison between OT- and VP-induced phosphoryla-
tion. 107 RL12-NP cells were incubated in non-supplemented (C), OT
(1 nM) or VP (1 nM) supplemented medium for 5 min. A Lysates
were submitted to immunoprecipitations with mAb 2A7 protein A-
like agarose conjugated before electrophoresis. Proteins transferred
on Immobilon were probed with PY-20 mAb specific for phosphoty-
rosine residues. B Quantification of p125FAK phosphorylation. Fluo-
rography from 3 separate experiments were analysed and expressed
as mean B SD of percentage of basal p125FAK phosphorylation.
ual IgG band that appeared on the membrane by reaction with the
HRP-conjugated anti-IgG or the reprobing of the membrane with
anti-FAK antibody. Both of the normalisations gave similar results.
Statistical Analyses
At each time point, values obtained from multiple experiments
were reported as percentage of mean basal phosphorylation value.
Compiled data from at least four separate experiments were com-
pared using the ANOVA test. Statistical significance was accepted
for p ^  0.05.
Results
Effect of Neurohypophysial Peptides on the
Phosphorylation of RL12-NP Proteins
To determine whether neurohypophysial-related pep-
tides increase protein phosphorylation in RL12-NP cells,
proteins were extracted from cells which had been incu-
bated with or without OT or VP at 1 nM for the indicated
time. Those peptides were appropriate candidates, ac-
cording to the specificity of the neurohypophysial recep-
tor expressed by those cells [14, 21] or by other T cell lines
[22, 23]. Five minutes after addition of either OT or VP,
the cells were lysed as described in experimental proce-
dures and lysates were analysed on Western blot with the
anti-phosphotyrosine PY-20 mAb.
This result is similar to the VP-induced tyrosine phos-
phorylation in fibroblasts [24] known to bear a V1-type
receptor [25]. VP and OT treatments modulate phosphor-
ylation of a wide range of proteins in the pre-T cell lines as
shown in figure 1. The rate of phosphorylation was
increased by OT and VP in the protein fractions between
100 and 200 kD. This rate was reduced after VP and even
reached a lower level after OT in fractions below 51 kD.
Nevertheless, the precise identity of phosphorylated pro-
teins could not be deduced from their apparent molecular
weight.
Lysates of 5-min untreated or treated cells were immu-
noprecipitated with anti-p125FAK 2A7 mAb. Western
blotting of immunoprecipitates analysed with PY-20 anti-
phosphotyrosine mAb is shown in figure 2. There was a
marked increase of the phosphorylation rate in two bands
with an apparent molecular weight of 125 and 130 kD
when RL12-NP cells were treated with OT for 5 min. An
increase was also observed in VP-treated RL12-NP cells
(fig. 2A). Densitometric analysis revealed that OT-in-
duced p125FAK phosphorylation twice as high as VP (fig.
2B). Statistical analyses confirmed a significant difference
between VP- and OT-induced p125FAK phosphorylation
(VP vs. control C; p ! 0.05, OT vs. C: p ! 0.01, OT vs. VP:
p ! 0.05 using ANOVA test).
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Fig. 3. Upper panel: Time course of
phosphorylation in anti-p125FAK immuno-
precipitates of proteins extracted from OT-
stimulated RL12-NP cells. RL12-NP cells
were stimulated during various times in ab-
sence (–) or in presence (+) of OT (1 nM)
before addition of cold DPBS w/o Ca/Mg.
Lysates were submitted to immunoprecipi-
tations with mAb 2A7 protein A-like agarose
conjugated before electrophoresis. Anti-
PTyr: proteins transferred on Immobilon
were probed with PY-20 mAb specific for
phosphotyrosine residues. Anti-FAK: the
same membrane was stripped and blotted
with 2A7 mAb to demonstrate similar load-
ing. Lane C is control mAb 2A7 protein A-
like agarose conjugated probed with anti-
IgG second antibody alone. IR proteins were
visualised by fluorography. Lower panel:
Analysis of the time course of phosphoryla-
tion induced by OT and VP in RL12-NP
cells. Each point represents the mean and
vertical bars represent the SD of at least four
separate experiments. Upper left corner: rel-
ative intensity of p125FAK phosphorylation
induced by OT. Lower left corner: relative
intensity of p125FAK phosphorylation in-
duced by VP. Upper right corner: relative
intensity of p130 phosphorylation induced
by OT. Upper left corner: relative intensity
of p130 phosphorylation induced by VP.
* p ! 0.05: OT- or VP-induced phosphoryla-
tion vs. basal phosphorylation at each time
(ANOVA test).
Time Course of Tyrosine Phosphorylation of p125FAK
in RL12-NP Cells
RL12-NP cells were then incubated with OT or VP
(1 nM) during the indicated time, immunoprecipitations
with 2A7 mAb protein A-like agarose-conjugated and a
two-step revelation was performed according to the proce-
dure described (fig. 3).
The phosphorylation rate was markedly increased in
two bands located at 125 kDa (assumed to be p125FAK)
and 130 kDa. The 97 kD Ig band represents a single
dimer of heavy Ig chains [26]. This is shown in figure 3
(lane C) where 2A7 mAb linked to a protein-A-like aga-
rose was probed with HRP-conjugated anti-IgG alone. As
precipitates were eluted by boiling for 3 min in SDS sam-
ple buffer, a 148-kDa IgG1 band appeared as 2A7 mAb
released from protein-A-like agarose as shown by the
same band in control immunoprecipitates in figure 3
(lane C). To demonstrate a similar loading of the immu-
noprecipitated proteins, anti-phosphotyrosine mAb was
stripped as described in ‘Material and Methods’ and blot-
ted with 2A7 mAb in the same two-step procedure. Only
the 125-kD band appeared on this blot (fig. 3, anti-FAK)
with similar intensities in each conditions. Similar fea-
tures were obtained when VP was used instead of OT.
The fluorography was quantified by a Bio-Rad GS-700
imaging densitometer and Molecular Analyst 1.4 Bio-Rad
program in order to estimate the time course evolution of
phosphorylation induced by OT or VP (fig. 3, lower
panel). From 1 to 10 min in basal conditions, there was no
significant variation in the phosphorylation rate of
p125FAK. With OT at 1 nM, there was a time-dependent
phosphorylation of the p125FAK and of the 130-kDa pro-
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Fig. 4. Inhibition of OT-induced phosphorylation by a V1 antago-
nist. 107 RL12-NP cells were incubated in non-supplemented (–), OT
(1 nM)-supplemented medium (+) for 1 or 5 min, or with OT (1 nM)
and V1 antagonist 10 nM for 5 min (+AV1-R). A Lysates were sub-
mitted to immunoprecipitations with mAb 2A7 protein-A-like aga-
rose conjugated before electrophoresis. Proteins transferred on Im-
mobilon were probed with PY-20 mAb. B Quantification of p125FAK
phosphorylation. Fluorography from 3 separate experiments were
analysed and expressed as mean B SD of percentage of basal
p125FAK phosphorylation.
Fig. 5. Paxillin phosphorylation under OT stimulation. 107 RL12-
NP cells were incubated in non-supplemented (–), or OT (1 nM)-sup-
plemented medium (+) for 1, 5 or 10 min. Lysates were submitted to
immunoprecipitations with anti-paxillin mAb 349 (ICN Flow) pro-
tein A-like agarose conjugated before electrophoresis. Proteins trans-
ferred on Immobilon were probed with PY-20 mAb specific for phos-
photyrosine residues.
tein (upper graphs) leading to more than 3-fold in the OT-
stimulated band versus basal conditions. VP also induced
the phosphorylation of both p125FAK and the 130-kDa
protein (lower graphs) which reached a double intensity
compared to the basal level after 5 min. VP-induced phos-
phorylation of p125FAK reached a maximum after 1 min,
while OT-induced phosphorylation increased until 5 min
and decreased after 10 min.
Inhibition of VP- and OT-Induced Phosphorylation by
a Specific V1 Antagonist
The effects of an anti-V1 antagonist could be evidenced
in OT-stimulated RL12-NP cells. This antagonist reduced
the phosphorylation of p125FAK with a high potency, being
already active at 10 nM (fig. 4A, B). Statistical analysis con-
firmed that the OT-induced phosphorylation of p125FAK
was significantly reduced by addition of the V1 antagonist
(OT at 5 min vs. basal at 5 min: p ! 0.01; OT at 5 min vs.
OT + V1 antagonist at 5 min: p ! 0.05 using ANOVA test).
The phosphorylation of p125FAK induced by VP was also
inhibited by a V1 antagonist (data not shown).
Effect of Neurohypophysial Peptides on Paxillin
Phosphorylation
When an anti-paxillin instead of 2A7 mAb was used to
immunoprecipitate RL12-NP lysates, the stimulation of
paxillin by neurohypophysial peptides could be evidenced
in RL12-NP cells.
Figure 5 shows that paxillin phosphorylation is in-
creased by OT with a time course similar to p125FAK
phosphorylation. However, the paxillin phosphorylation
decreased under the basal level at 10 min. VP also
induced paxillin phosphorylation with a similar time
course (data not shown).
Discussion
This study shows that p125FAK proteins are present in
RL12-NP pre-T cell line, and that neurohypophysial pep-
tides are able to stimulate their phosphorylation in a time-
dependent manner with a maximum occurring within 1–
5 min. These results concord with previous observations
[27, 28] which showed that VP stimulates p125FAK and
paxillin phosphorylation in a fibroblast cell line. How-
ever, OT appears to be more potent than VP to induce
phosphorylation in RL12-NP pre-T cell line.
The rapidity of neuropeptide-induced phosphoryla-
tion is consistent with mechanisms of early activation and
indicates that p125FAK may function as a downstream ele-
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ment in a neuropeptide-stimulated tyrosine kinase path-
way. The 130-kDa protein detected in anti-p125FAK im-
munoprecipitates the phosphorylation of which increased
together with p125FAK, could represent a coprecipitating
substrate of p125FAK, a coprecipitating protein kinase or
a protein that non-specifically bind to the immune com-
plexes. It is interesting to note that, like the p125FAK,
there is a protein of 130 kDa called p130Cas, which is a
major tyrosine phosphorylated protein in src-trans-
formed fibroblasts which intervenes in adhesion mecha-
nisms, and which forms stable complexes with activated
forms of pp60v-src [29–33]. The p130Cas may be phosphor-
ylated by VP in a fibroblastic model [27]; it may associate
both in vitro and in vivo with p125FAK, and it may func-
tion as a mediator in transduction of adhesion signals
[34, 35]. The phosphorylation of the p125FAK-associated
proteins p130 (probably p130Cas) and paxillin was also
evidenced in RL12-NP cells. It has been suggested that
p130Cas and paxillin phosphorylations are regulated by
p125FAK because these proteins colocalize in cellular fo-
cal adhesions, are physically associated with p125FAK and
are coordinately phosphorylated on tyrosine residues in
response to multiple stimuli [1]. This study shows that
neurohypophysial peptides induce the phosphorylation
of at least three focal adhesion-associated proteins in
RL12-NP pre-T cells.
RL12-NP is a pre-T cell line derived from a thymic lym-
phoma induced by X-ray irradiation of C57BL mice.
RL12-NP cells are characterised by the absence of CD4
and CD8 differentiation markers (like double-negative
thymocytes), and by the presence of functional neurohy-
pophysial receptors with characteristics close to the V1
subtype expressed in the thymus [36, 37]. Thus, a series of
phenotypical and functional aspects are concordant be-
tween thymocytes and RL12-NP cells. Since freshly iso-
lated thymocytes are highly heterogeneous, there is an
advantage to use of homogenous cell line. In addition, the
inhibition of p125FAK phosphorylation in RL12-NP cells
by an antagonist directed against a V1 receptor confirms
our previous study which showed that pre-T cells bear a
V1 receptor [14].
The precise nature of the thymic natural ligand inter-
acting with V1 receptors on pre-T cells may be questioned.
The predominant neurohypophysial peptide expressed in
the thymus is OT and only mAbs to OT are able to acti-
vate cytokine secretion by TEC [38]. As shown in this
study, OT is more potent than VP to induce p125FAK
phosphorylation and this OT effect is inactivated by a V1
antagonist. These findings suggest that OT could be a nat-
ural ligand of the V1 receptors borne by thymic T cells. It
should be noticed that OT has already been shown to act
through V1-type receptors in other systems [39, 40].
The p125FAK has been shown to be a potential activa-
tor of the adaptator protein system Grb2/SoS leading to
stimulation of the ras/MAPK pathway [41] and also to act
through the PI 3-kinase pathway [42, 43]. Therefore, the
mitogenic effect of OT and VP observed on human and
murine freshly isolated thymocytes could be mediated by
activation of p125FAK.
The implication of p125FAK in thymic T-cell develop-
ment and activation is suggested by several experimental
facts such as the presence of p125FAK mRNA in human T
and B cells [5], as well as in murine thymocytes at differ-
ent differentiation stages [44]. A p125FAK-related protein
(called FakB) has been shown to be phosphorylated fol-
lowing TcR activation [45] and p125FAK itself is synergis-
tically stimulated in CD4+ cell blasts and Jurkat T cell
line by integrins and TcR engagement [46, 47]. With
regard to the kinetic of p125FAK phosphorylation, the
transient maximum observed with OT has also been
shown in T cells stimulated by chemokine RANTES [16],
while TCR engagement or integrin activation induced a
more sustained phosphorylation of p125FAK [46–49]. Fur-
thermore, while it is well established that apoptosis is cru-
cial in the process of thymic T cell selection [50], a rela-
tionship has been shown in human tumor cells between
the attenuation of expression of p125FAK and the induc-
tion of apoptosis [51]. Finally, focal adhesion proteins
play a fundamental role in early embryogenesis as evi-
denced by the defect in mesoderm induction in p125FAK
knockout mice [52, 53]. The observations of numerous
points of focal adhesion using electron microscopy consti-
tuted a preliminary hypothesis for the investigation of
p125FAK implication in T cell development. Our results
confirm this hypothesis and provide a biochemical link
with the ultrastructural data [15].
p125FAK has been discovered in a model of v-src-trans-
formed chicken embryo [2] and was shown to be an acti-
vator of pp60src [54]. Moreover, increased p125FAK ex-
pression is associated with invasive and metastatic tu-
mour phenotype [55–59]. Some p125FAK antisenses have
been proposed as pharmacological agents against cancer
[60]. Thus, the basal and stimulated phosphorylation of
p125FAK in a T cell line derived from a radioinduced lym-
phoma could be correlated with the immortalised pheno-
type. The inhibitory effect of a V1 receptor antagonist on
p125FAK phosphorylation induced by neurohypophysial
peptides also suggests that such a pharmacological agent
could be tested for its putative antiproliferative and anti-
metastatic actions.
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The stimulation of pre-T cell kinases implicated in
adhesion and proliferation by signals encountered within
thymic microenvironment further supports the existence
of a cryptocrine signalling effective in vivo between TEC
and developing T lymphocytes [8, 11, 38]. Obviously, the
phosphorylation of focal adhesion kinases induced by nat-
ural thymic peptide ligands deserves to be further investi-
gated as an important pathway of T cell differentiation
and selection.
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